Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
- SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE
- Satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE
Berlin, Germany, 10 June, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it will be presenting a poster demonstrating the efficacy of its somatostatin receptor 2 (SST2) antagonist, SS0110 (satoreotide), relative to SST2-targeting agonists, at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held 8-11 June 2024 in Toronto, Canada.
